These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38952084)

  • 1. Altered desensitization and internalization patterns of rodent versus human glucose-dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge.
    Gasbjerg LS; Rasmussen RS; Dragan A; Lindquist P; Melchiorsen JU; Stepniewski TM; Schiellerup S; Tordrup EK; Gadgaard S; Kizilkaya HS; Willems S; Zhong Y; Wang Y; Wright SC; Lauschke VM; Hartmann B; Holst JJ; Selent J; Rosenkilde MM
    Br J Pharmacol; 2024 Jul; ():. PubMed ID: 38952084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human GIP(3-30)NH
    Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
    Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internalization and desensitization of the human glucose-dependent-insulinotropic receptor is affected by N-terminal acetylation of the agonist.
    Ismail S; Dubois-Vedrenne I; Laval M; Tikhonova IG; D'Angelo R; Sanchez C; Clerc P; Gherardi MJ; Gigoux V; Magnan R; Fourmy D
    Mol Cell Endocrinol; 2015 Oct; 414():202-15. PubMed ID: 26225752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system.
    Gabe MBN; van der Velden WJC; Gadgaard S; Smit FX; Hartmann B; Bräuner-Osborne H; Rosenkilde MM
    Basic Clin Pharmacol Toxicol; 2020 Jun; 126 Suppl 6(Suppl 6):122-132. PubMed ID: 31299132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling.
    Tseng CC; Zhang XY
    Endocrinology; 2000 Mar; 141(3):947-52. PubMed ID: 10698169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
    Ravn P; Madhurantakam C; Kunze S; Matthews E; Priest C; O'Brien S; Collinson A; Papworth M; Fritsch-Fredin M; Jermutus L; Benthem L; Gruetter M; Jackson RH
    J Biol Chem; 2013 Jul; 288(27):19760-72. PubMed ID: 23689510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
    PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Cell Surface Expression and Linker Sequence on the Recruitment of Arrestin to the GIP Receptor.
    Al-Sabah S; Adi L; Bünemann M; Krasel C
    Front Pharmacol; 2020; 11():1271. PubMed ID: 32903502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice.
    Perry RA; Craig SL; Ng MT; Gault VA; Flatt PR; Irwin N
    Clin Med Insights Endocrinol Diabetes; 2019; 12():1179551419875453. PubMed ID: 31548798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
    Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes.
    Kizilkaya HS; Sørensen KV; Madsen JS; Lindquist P; Douros JD; Bork-Jensen J; Berghella A; Gerlach PA; Gasbjerg LS; Mokrosiński J; Mowery SA; Knerr PJ; Finan B; Campbell JE; D'Alessio DA; Perez-Tilve D; Faas F; Mathiasen S; Rungby J; Sørensen HT; Vaag A; Nielsen JS; Holm JC; Lauenborg J; Damm P; Pedersen O; Linneberg A; Hartmann B; Holst JJ; Hansen T; Wright SC; Lauschke VM; Grarup N; Hauser AS; Rosenkilde MM
    Nat Metab; 2024 Jul; 6(7):1268-1281. PubMed ID: 38871982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor.
    Yuliantie E; van der Velden WJC; Labroska V; Dai A; Zhao F; Darbalaei S; Deganutti G; Xu T; Zhou Q; Yang D; Rosenkilde MM; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2021 Oct; 192():114715. PubMed ID: 34339714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant.
    Yammine L; Picatoste B; Abdullah N; Leahey RA; Johnson EF; Gómez-Banoy N; Rosselot C; Wen J; Hossain T; Goncalves MD; Lo JC; Garcia-Ocaña A; McGraw TE
    Mol Metab; 2023 Dec; 78():101831. PubMed ID: 37925022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand.
    Yaqub T; Tikhonova IG; Lättig J; Magnan R; Laval M; Escrieut C; Boulègue C; Hewage C; Fourmy D
    Mol Pharmacol; 2010 Apr; 77(4):547-58. PubMed ID: 20061446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist.
    Lewis JT; Dayanandan B; Habener JF; Kieffer TJ
    Endocrinology; 2000 Oct; 141(10):3710-6. PubMed ID: 11014226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.
    Harada N; Yamada Y; Tsukiyama K; Yamada C; Nakamura Y; Mukai E; Hamasaki A; Liu X; Toyoda K; Seino Y; Inagaki N
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E61-8. PubMed ID: 17971513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model.
    Weaver RE; Donnelly D; Wabitsch M; Grant PJ; Balmforth AJ
    Int J Obes (Lond); 2008 Nov; 32(11):1705-11. PubMed ID: 18779825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of a GPCR by β-Arrestin2-Mediated Switch from an Endosomal to a TGN Recycling Pathway.
    Abdullah N; Beg M; Soares D; Dittman JS; McGraw TE
    Cell Rep; 2016 Dec; 17(11):2966-2978. PubMed ID: 27974210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity.
    Mohammad S; Patel RT; Bruno J; Panhwar MS; Wen J; McGraw TE
    Mol Cell Biol; 2014 Oct; 34(19):3618-29. PubMed ID: 25047836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.